Please assess the completion status of the following clinical trial:

Trial Title: Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women at least 16 yers of age (or minimum age as determined by local regulatory authorities)~* HIV-1 RNA viral load of greater than or equal to 5,000 copies/mL~* Stable pre-study antiretroviral regimen, or on no antiretroviral agents, for at least 4 weeks~* Documented genotypic or phenotypic resistance to three of the four antiretroviral drug classes, OR, Antiretroviral-class experience greater than or equal to 6 months (sequential or cumulative) with at least three of the following: One nucleoside or nucleotide reverse transcriptase inhibitor, one non-nucleoside reverse transcriptase inhibitor, two protease inhibitors (excluding low-dose ritonavir) and/or enfuvirtide~* Be willing to remain on randomized treatment without any changes or additions to the OBT regimen, except for toxicity management or upon meeting criteria for treatment failure~* A negative urine pregnancy test at the baseline visit for Women of Child Bearing Potential (WOCBP)~* Effective barrier contraception for WOCBP and males~Exclusion Criteria:~* Patients requiring treatment with more than 6 antiretroviral agents (excluding low-dose ritonavir)~* Prior treatment with maraviroc (UK-427,857) or another experimental HIV entry inhibitor for more than 14 days~* Suspected or documented active, untreated HIV-1 related opportunistic infection (OI) or other condition requiring acute therapy~* Treatment for an active opportunistic infection, or unexplained temperature \>38.5 degrees Celsius for 7 consecutive days~* Active alcohol or substance abuse sufficient, in the Investigator's judgment, to prevent adherence to study medication and/or follow up~* Lactating women, or planned pregnancy during the trial period~* Significant renal insufficiency~* Initiating therapy with a potentially myelosuppressive, neurotoxic, hepatotoxic and/or cytotoxic agent within 60 days prior to randomization or the expected need for such therapy during the study period~* Documented or suspected acute hepatitis or pancreatitis within 30 days prior to randomization~* Significantly elevated liver enzymes or cirrhosis~* Significant neutropenia, anemia or thrombocytopenia~* Malabsorption or an inability to tolerate oral medications~* Certain medications~* Malignancy requiring parenteral chemotherapy that must be continued for the duration of the trial~* X4- or dual/mixed-tropic virus or repeated assay failure~* Any other clinical condition that, in the Investigator's judgement, would potentially compromise study compliance or the ability to evaluate safety/efficacy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None
- 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete